CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needledevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01598194
NCT01598194N/ACompleted
CompareCT.gov

Prospective Comparison of a Novel 22-gauge Core Biopsy Needle With Reverse Bevel Design to a Standard Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) Needle for Diagnosis of Solid Pancreatic Mass Lesions

M.D. Anderson Cancer Center·interventional·Posted May 15, 2012·Updated Dec 27, 2018

In Brief

A clinical study evaluating Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle for Solid Pancreatic Mass Lesions and Malignant Neoplasm of Pancreas. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to compare the performance of a newly available needle with reverse bevel design (called the EchoTip® Procore™ needle) with standard needles to see which needle gives better diagnostic information for pancreatic lesions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Pancreatic Mass Lesions, Malignant Neoplasm of Pancreas
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 15, 2012
Enrollment StartJan 30, 2012
Primary CompletionJul 6, 2017
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 14.1 years ago

Interventions

Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needledevice

Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.